@article{937cd2bfaef74f9d8ce5d5cc298297d6,
title = "Encouraging participation in colorectal cancer screening for people with schizophrenia: A randomized controlled trial",
abstract = "Objective: We examined the efficacy of a case management approach to improve participation in colorectal cancer screening among people with schizophrenia. Methods: This was a randomized, parallel group trial. We recruited outpatients with schizophrenia aged 40 years or over from two psychiatric hospitals in Japan. Participants were randomly assigned (1:1) to treatment as usual or case management intervention plus treatment as usual using a web-based system. Attending clinicians and participants were unmasked to the allocation. Case management included education and patient navigation for colorectal cancer screening using a fecal occult blood test. Treatment as usual included direct mail government recommendations. The primary endpoint was participation in colorectal cancer screening assessed using municipal records. We also assessed the secondary endpoint of participation in other cancer screenings (lung, gastric, breast, and cervical). Results: Between 3 June and 9 September 2019, 172 eligible participants were randomly assigned to the case management plus treatment as usual group (n = 86) or treatment as usual group (n = 86). One participant was ineligible and another withdrew consent; both were excluded from analysis. A significantly higher proportion of participants received colorectal cancer screening in the case management plus treatment as usual group than in the treatment as usual group (40 [47.1%] of 85 participants vs. 10 [11.8%] of 85 participants, p < 0.0001). The proportion of lung cancer screening also increased. No serious adverse events associated with the study intervention occurred. Conclusion: The case management intervention to encourage participation in colorectal cancer screening was effective for patients with schizophrenia.",
keywords = "cancer screening, case management, patient navigation, randomized controlled trial, schizophrenia",
author = "Masaki Fujiwara and Yuto Yamada and Taichi Shimazu and Masafumi Kodama and Ryuhei So and Takanori Matsushita and Yusaku Yoshimura and Shigeo Horii and Maiko Fujimori and Hirokazu Takahashi and Naoki Nakaya and Kyoko Kakeda and Tempei Miyaji and shiro Hinotsu and Keita Harada and Hiroyuki Okada and Yosuke Uchitomi and Norihito Yamada and Masatoshi Inagaki",
note = "Funding Information: Masaki Fujiwara reports grants from the Japanese Ministry of Health, Labour and Welfare (MHLW), received during the conduct of the study and personal fees from Meiji outside the submitted work. Masafumi Kodama reports grants from the MHLW, received during the conduct of the study. Ryuhei So reports personal fees from Kagakuhyronsha, Medical Review, Otsuka, Igaku Shoin, and CureApp outside the submitted work. Yusaku Yoshimura reports personal fees from Otsuka, Janssen, and Meiji outside the submitted work. Tempei Miyaji reports grants from the MHLW, received during the conduct of the study. Yosuke Uchitomi reports grants from the MHLW, and grants and non‐financial support from the Japan Health Research Promotion Bureau and the National Cancer Center Japan, received during the conduct of the study. Norihito Yamada reports grants from the MHLW, received during the conduct of the study; grants and personal fees from Daiichi Sankyo, Eisai, and Takeda; and personal fees from Otsuka, MSD, UCB, and Sumitomo Dainippon outside the submitted work. Masatoshi Inagaki reports grants from the MHLW, received during the conduct of the study; personal fees from Technomics, Fuji Keizai, Novartis, Pfizer, MSD, Yoshitomiyakuhin, Meiji, Eisai, Otsuka, Sumitomo Dainippon, Mochida, Janssen, Takeda, and Eli Lilly; and grants from Otsuka, Eisai, Daiichi Sankyo, Pfizer, Astellas, MSD, Takeda, Fujifilm, Shionogi, and Mochida outside the submitted work. The other authors have nothing to disclose. Funding Information: We thank all the staff of the outpatient service at the Okayama Psychiatric Medical Center and Zikei Hospital for their support in the study and all patients who participated in the study. We also thank Miyuki Kurosaki and Kumiko Seike for their support with data management, Shoko Yoshimoto and Sakura Hino for logistic assistance, and the staff of Okayama City Health Center (Hiroaki Matsuoka and his staff) who provided kind suggestions about the study and searched the database for cancer screening records. Finally, we thank Analisa Avila, ELS, and Diane Williams, PhD, of Edanz ( https://jp.edanz.com/ac ) for editing a draft of this manuscript. This work was supported by the Research for Promotion of Cancer Control Programs from the Japanese Ministry of Health, Labour and Welfare (H30‐Cancer Control‐general‐006). The work was endorsed by the Japan Supportive, Palliative and Psychosocial Oncology Group (J‐SUPPORT) as the J‐SUPPORT 1901 study, funded by the National Cancer Center Research and Development Fund (30A‐11) and the National Center Consortium in Implementation Science for Health Equity (N‐EQUITY), which is funded by the Japan Health Research Promotion Bureau (JH) Research Fund (2019‐(1)‐4). Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2021",
month = oct,
doi = "10.1111/acps.13348",
language = "English",
volume = "144",
pages = "318--328",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "4",
}
